Tethra Biosciences

FogPharma (formerly Tethra Biosciences) is a clinical-stage biopharmaceutical company dedicated to drugging the "undruggable" through its proprietary Helicon™ polypeptide platform. The company develops hyper-stabilized alpha-helical peptides that combine the cell-permeability of small molecules with the high specificity and potency of biologics. Their lead candidate, FOG-001, is a first-in-class intracellular TCF-blocking beta-catenin inhibitor currently being evaluated in Phase 1/2 clinical trials for colorectal cancer and other solid tumors. FogPharma's pipeline also includes programs targeting other challenging drivers of cancer, such as TEAD, STAT3, and KRAS. Founded by renowned chemical biologist Dr. Greg Verdine, the company is headquartered in Cambridge, Massachusetts, and is backed by leading life science investors.